AHC
TCRT icon

Adell Harriman & Carpenter’s Alaunos Therapeutics TCRT Stock Holding History

Adell Harriman & Carpenter’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-154
Closed -$134K – 145
2019
Q2 		$134K Hold
154
– – 0.03% 132
2019
Q1 		$88.7K Hold
154
– – 0.02% 141
2018
Q4 		$43.1K Hold
154
– – 0.01% 145
2018
Q3 		$73.7K Hold
154
– – 0.01% 144
2018
Q2 		$69.5K Hold
154
– – 0.01% 148
2018
Q1 		$90.3K Hold
154
– – 0.02% 144
2017
Q4 		$95.3K Hold
154
– – 0.02% 141
2017
Q3 		$141K Buy
+154
New +$137K 0.03% 138

Other funds holding TCRT

MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Adell Harriman & Carpenter's TCRT Position: Q3 2019 in Review

Adell Harriman & Carpenter sold out of Alaunos Therapeutics (TCRT) in Q3 2019, closing a stake of 154 shares — an estimated $134K sold.

Adell Harriman & Carpenter first reported a position in TCRT in Q3 2017 and held it in 8 quarters. The position peaked at $141K in Q3 2017. 142 funds tracked by Wall St. Rank hold TCRT as of Q3 2019.

  • Adell Harriman & Carpenter reported no remaining Alaunos Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Adell Harriman & Carpenter sold 154 Alaunos Therapeutics shares in Q3 2019, an estimated $134K.
  • Adell Harriman & Carpenter first reported a position in Alaunos Therapeutics in Q3 2017 and held it in 8 quarters.
  • Adell Harriman & Carpenter's Alaunos Therapeutics position peaked at $141K in Q3 2017.
  • 142 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q3 2019.

Based on Adell Harriman & Carpenter's 13F filing for Q3 2019, filed 8 Nov 2019.